Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

, 4% placebo), hypertension (5% CIMZIA, 2% placebo), nasopharyngitis (5% CIMZIA, 1% placebo), back pain (4% CIMZIA, 1% placebo), pyrexia (3% CIMZIA, 2% placebo), pharyngitis (3% CIMZIA, 1% placebo), rash (3% CIMZIA, 1% placebo), acute bronchitis (3% CIMZIA,1% placebo), fatigue (3% CIMZIA, 2% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving CIMZIA than in controls.  These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs.  Patients receiving CIMZIA 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving CIMZIA 200mg every other week.  The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for CIMZIA and 2.5% for placebo.

Please see full prescribing information at www.cimzia.com before prescribing.

For further Information:
Andrea Levin, Senior Manager, Communications & PR
(770) 970-8352, Andrea.Levin@ucb.com

Dena Koklanaris, Cooney/Waters Group
(212) 886-2228, DKoklanaris@cooneywaters.com

About UCB
UCB, Brussels, Belgium (www.ucb-usa.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

For fu
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)... Vittamed Corporation , a neurodiagnostics medical device company based in ... (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd ... " Teo Forcht Dagi is an experienced leader ... capital," said Remis Bistras , President and CEO of ... and entrepreneurial expertise to our Board." Dr. Dagi ...
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:9/1/2014)... (PRWEB) September 02, 2014 Top10BestSEOHosting.com is ... recently compared many top web hosting companies and announced ... hosting suppliers in August. , GreenGeeks ( http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... from the USA. The company has a lot of ... always get great products at low rates. , ...
(Date:9/1/2014)... was associated with mental health and substance use ... protect teens from the consequences of cyberbullying and ... Author: Frank J. Elgar, Ph.D., of McGill University, ... in 5 adolescents has experienced recent online bullying ... risk of mental health problems in teens as ...
(Date:9/1/2014)... 01, 2014 Liver is the largest organ ... that helps the body in barring itself from poisons, helps ... energy. Liver also plays many important functions such as protein ... , Many illnesses can affect the liver, an organ ... cage on the right side of the abdomen, reducing its ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment ... markets (the US, France, Italy, Germany, Spain and the ... by 2018. , The competitive landscape in the B-cell ... and the UK is poised to undergo a dramatic ... four largest B-cell NHL indications, which includes Diffuse Large ...
(Date:9/1/2014)... D.C. (PRWEB) September 01, 2014 The ... pleased to announce that Dawn Bazarko, DNP, MPH, RN, ... Fellows of the American Academy of Nursing. They will ... MBA, RN-BC, CCM, FACHE, whose induction we reported last ... October 18, 2014, during the 2014 American Academy of ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
... in the early detection of coronary heart disease (CHD) between ... 45-64 have undetected or silent myocardial infarctions, suggesting a general ... a doctors gender may hinder early hinder early diagnosis of ... by Dr Ann Adams of Warwick Medical School at the ...
... indoor mould improves the symptoms of people with asthma. , ... is among the highest in the world, with 260,000 people ... admissions for adults 12 per cent more than anywhere else ... asked patients with asthma living in two areas of South ...
... Memry Corporation,(Amex: MRY ), a leading provider ... announced today that it will release its fiscal,fourth quarter ... 17,after the market closes. The company will host ... of the management team on Tuesday, September 18 at ...
... ... Refined Cats, Palates, CHELMSFORD, Mass., Sept. 5 ... natural food and treats for pets,is launching a NEW offering for ... real,seafood and poultry morsels and an array of fresh fruits and ...
... choices for older Americans, researchers find , WEDNESDAY, Sept. ... that charge higher co-pays for brand name or non-preferred ... peers who have a flat co-pay for all prescription ... a tough decision for older Americans: Spend more or ...
... Medical,Organizations Growing Rapidly with Thousands of Community Members ... introduced Lance Hill,as the new CEO of the ... physicians, researchers, and medical organizations worldwide. Members,use Within3,s ... as a,professional tool, where they can develop their ...
Cached Medicine News:Health News:Research says doctor's gender may hinder early diagnosis of heart disease in women 2Health News:Research says doctor's gender may hinder early diagnosis of heart disease in women 3Health News:Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call 2Health News:Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees 2Health News:Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees 3Health News:High Co-Pays Cause Seniors to Go Without Meds 2Health News:Cleveland-based Health Care Tech Company Within3 Names New CEO 2
... Mini low cost Incubators. Bench top ... excellent incubation results. Aluminum lined chamber ... and I104025 incubators contain removable perforated ... easy decontamination. Thermometer port on top ...
Binocular indirect ophthalmic lenses. Pediatric ophthalmoscopy / vetinary applications....
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Medicine Products: